90Y-edotreotide for metastatic carcinoid refractory to octreotide

Journal of Clinical Oncology

Volumn 28, Issue 10, 2010, Pages 1652-1659

  Bushnell Jr , David L ^a   O'Dorisio, Thomas M ^a   O'Dorisio, M Sue ^a   Menda, Yusuf ^a   Hicks, Rodney J ^a   Van Cutsem, Eric ^a   Baulieu, Jean Louis ^a   Borson Chazot, Francoise ^a   Anthony, Lowell ^a   Benson, Al B ^a   Oberg, Kjell ^a   Grossman, Ashley B ^a   Connolly, Mary ^a   Bouterfa, Hakim ^a   Li, Yong ^a   Kacena, Katherine A ^a   LaFrance, Norman ^a   Pauwels, Stanislas A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EDOTREOTIDE; EDOTREOTIDE Y 90; OCTREOTIDE; ONALTA; UNCLASSIFIED DRUG; YTTRIUM 90; 90Y OCTREOTIDE, DOTA TYR(3); 90Y-OCTREOTIDE, DOTA-TYR(3)-; DRUG DERIVATIVE; YTTRIUM;

ADULT; ANEMIA; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ASCITES; ASTHENIA; BACKACHE; BENIGN TUMOR; CANCER SURVIVAL; CARCINOID; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; FLUSHING; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; KIDNEY FAILURE; LEUKOPENIA; LOWER ABDOMINAL PAIN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OLIGURIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RHINOPHARYNGITIS; SIDE EFFECT; SYMPTOM; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; VOMITING; WEAKNESS; WEIGHT REDUCTION; ADOLESCENT; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG RESISTANCE; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOID TUMOR; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; YTTRIUM RADIOISOTOPES;

EID: 77950506150     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.8585     Document Type: Article

References (34)

1. Crocetti E, Paci E: Malignant carcinoids in the USA, SEER 1992-1999: An epidemiological study with 6830 cases. Eur J Cancer Prev 12:191-194, 2003
2. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97:935-959, 2003
3. Maggard MA, O'Connell JB, Ko CY: Updated population-based review of carcinoid tumors. Ann Surg 240:117-122, 2004 (Pubitemid 38808243)
4. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Limited-Use, Nov 2006 Sub (1973-2004) - Linked To County Attributes - Total U.S., 1969-2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission. In addition, the 20 year limited-duration prevalence session available via the Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seer.cancer.gov/seerstat) version 6.3.5
5. Jensen RT: Carcinoid and pancreatic endocrine tumors: Recent advances in molecular pathogenesis, localization and treatment. Curr Opin Oncol 2:368-377, 2000
6. Vinik A, Moattari AR: Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci 34:14S-27S, 1989
7. Perry RR, Vinik AI: Endocrine tumors of the gastrointestinal tract. Annu Rev Med 47:57-68, 1996 (Pubitemid 26138872)
8. Janson ET, Holmberg L, Stridsberg M, et al: Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 8:685-690, 1997 (Pubitemid 27372168)
9. Rougier P, Mitry E: Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 62:73-78, 2000 (Pubitemid 30665943)
10. Sun W, Lipsitz S, Catalano P, et al: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group study E1281. J Clin Oncol 23:4897-4904, 2005 (Pubitemid 46223995)
11. Kaltsas GA, Mukherjee JJ, Isidori A, et al: Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil. Clin Endocrinol (Oxf) 57:169-183, 2002 (Pubitemid 34989093)
12. Wynick D, Anderson JV, Williams SJ, et al: Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995). Clin Endocrinol (Oxf) 30:385-388, 1989 (Pubitemid 19110010)
13. Ruszniewski P, Ish-Shalom S, Wymenga M, et al: Rapid and sustained relief from the symptoms of carcinoid syndrome: Results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 80:244-251, 2004 (Pubitemid 40187010)
14. Stolz B, Weckbecker G, Smith-Jones PM, et al: The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3] octreotide (90YSMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med 25:668-674, 1998 (Pubitemid 28377028)
15. de Jong M, Breeman WA, Bernard BF, et al: Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 42:1841-1846, 2001
16. Waldherr C, Pless M, Maecke HR, et al: Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43:610-616, 2002 (Pubitemid 34507110)
17. Krenning EP, Valkema R, Pauwels S, et al: Radiolabeled somatostatin analogue(s): Peptide receptor scintigraphy and radionuclide therapy, in Mignon M, Colombel JF (eds): Recent Advances in the Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumors. Paris, France, John Libbey Eurotext, 1999
18. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992 (Pubitemid 23008970)
19. Krabbe PF, Peerenboom L, Langenhoff BS, et al: Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Qual Life Res 13:1247-1253, 2004 (Pubitemid 39149608)
20. Reference deleted
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
22. Otte A, Herrmann R, Heppeler A, et al: Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 26:1439-1447, 1999 (Pubitemid 29515605)
23. 90YDOTATOC): the IEO experience, in Chinol M, Paganelli G (eds): Radionuclide Peptide Cancer Therapy. New York, NY, Taylor & Francis Group, 2006
24. Valkema R, Pauwels S, Kvols LK, et al: Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36:147-156, 2006 (Pubitemid 43320450)
25. Perez E, Koniaris L, Snell S, et al: 7201 Carcinoids: Increasing incidence overall and disproportionate mortality in the elderly. World J Surg 31:1022-1030, 2007 (Pubitemid 46716758)
26. Anthony LB, Woltering EA, Espenan GD, et al: Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 32:123-132, 2002 (Pubitemid 34311078)
27. Arnold R, Rinke A, Klose KJ, et al: Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: A randomized trial. Clin Gastroenterol Hepatol 3:761-771, 2005 (Pubitemid 41116728)
28. Arnold R, Trautmann ME, Creutzfeldt W, et al: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38:430-438, 1996
29. Saltz L, Trochanowski B, Buckley M, et al: Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 72:244-248, 1993 (Pubitemid 23182080)
30. di Bartolomeo M, Bajetta E, Buzzoni R, et al: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: A study by the Italian Trials in Medical Oncology Group. Cancer 77:402-408, 1996 (Pubitemid 26023360)
31. Bushnell D, O'Dorisio T, Menda Y, et al: Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. J Nucl Med 44:1556-1560, 2003 (Pubitemid 39663323)
32. Bushnell D, Menda Y, O'Dorisio T, et al: Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment. Cancer Biother Radiopharm 19:35-41, 2004 (Pubitemid 38352283)
33. Jamar F, Barone R, Mathieu I, et al: 86YDOTA0)-D-Phe1-Tyr3-octreotide (SMT487) - a phase 1 clinical study: Pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 30:510-518, 2003 (Pubitemid 36559829)
34. Rolleman EJ, Valkema R, de Jong M, et al: Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 30:9-15, 2003 (Pubitemid 36692887)